Want to see FTH full AI Analyst Report?
Top Page
Faeth Therapeutics
(NASDAQ:FTH)
Select Model
Select Model
Rating:50Neutral
Price Target:
$27.00
▲(136.43% Upside)
Action:Reiterated
Date:08/04/26
The score is primarily held back by weak financial performance (no revenue, sizable losses, and ongoing cash burn), despite a low-debt balance sheet. Technicals are moderately supportive with a constructive longer-term trend and neutral momentum indicators. Valuation is penalized by a negative P/E and no dividend support, while the recent performance-based option plan is a modest positive but secondary versus the fundamental funding and profitability risks.
Positive Factors
Low Leverage / Strong Balance Sheet
Very low debt reduces near-term solvency risk and preserves financial flexibility to fund clinical programs or license deals over the next several quarters. A low-leverage profile supports strategic optionality (partnering, M&A, or targeted financings) without heavy interest burden.
Negative Factors
No Revenue / Persistent Losses
Faeth remains a pre-commercial biotech with no revenue and sustained net losses, meaning core operations are not self-sustaining. Over a multi-quarter horizon this keeps the company dependent on trial success and external funding, increasing execution risk if clinical setbacks occur.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Strong Balance Sheet
Very low debt reduces near-term solvency risk and preserves financial flexibility to fund clinical programs or license deals over the next several quarters. A low-leverage profile supports strategic optionality (partnering, M&A, or targeted financings) without heavy interest burden.
Read all positive factors
Faeth Therapeutics (FTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$702.21M
Dividend YieldN/A
Average Volume (3M)38.93K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue GrowthN/A
EPS Growth-518.34%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-146.83
Shares Outstanding25,778,753
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$55.44Price Target Upside385.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-51.61
Revenue Forecast (FY)N/A
Faeth Therapeutics Business Overview & Revenue Model
Company Description
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational a...
How the Company Makes Money
null...
Faeth Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -4.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -132.96M | 0.00 | -551.00K | -571.00K | -1.81M | -685.00K |
| EBITDA | -197.80M | -20.91M | -29.52M | -33.39M | -46.56M | -35.44M |
| Net Income | -195.53M | -21.09M | -30.16M | -34.10M | -48.59M | -36.79M |
Balance Sheet | ||||||
| Total Assets | 189.31M | 22.90M | 45.36M | 74.37M | 118.38M | 153.22M |
| Cash, Cash Equivalents and Short-Term Investments | 186.44M | 21.18M | 41.34M | 65.76M | 107.12M | 147.62M |
| Total Debt | 592.00K | 1.51M | 3.85M | 6.21M | 8.03M | 2.35M |
| Total Liabilities | 9.58M | 4.31M | 6.97M | 9.48M | 14.97M | 6.71M |
| Stockholders Equity | 172.96M | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M |
Cash Flow | ||||||
| Free Cash Flow | -33.86M | -20.47M | -24.82M | -32.20M | -39.35M | -32.28M |
| Operating Cash Flow | -33.86M | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M |
| Investing Cash Flow | -135.68M | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M |
| Financing Cash Flow | 183.88M | -645.00K | -787.00K | -11.17M | -287.00K | 163.94M |
Faeth Therapeutics Technical Analysis
Neutral
11.42
Price Trends
22.74
Positive
25.38
Positive
19.09
Positive
Market Momentum
1.14
Positive
51.19
Neutral
37.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FTH, the sentiment is Neutral. The current price of 11.42 is below the 20-day moving average (MA) of 29.23, below the 50-day MA of 22.74, and below the 200-day MA of 19.09, indicating a neutral trend. The MACD of 1.14 indicates Positive momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 37.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FTH.
Faeth Therapeutics Risk Analysis
Faeth Therapeutics disclosed 82 risk factors in its most recent earnings report. Faeth Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Faeth Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $20.54M | -0.35 | -264.79% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $702.21M | -0.18 | -283.67% | ― | ― | -518.34% | |
48 Neutral | $11.31M | -1.11 | -150.61% | ― | ― | 53.06% | |
43 Neutral | $7.67M | -0.25 | -100.90% | ― | 78.64% | 50.70% | |
41 Neutral | $5.22M | -0.17 | -423.84% | ― | -8.47% | 25.61% |
* Healthcare Sector Average
FTH
Faeth Therapeutics
25.50
17.26
209.50%
CLRB
Cellectar Biosciences
2.56
-2.31
-47.43%
COCP
Cocrystal Pharma
0.98
-0.67
-40.61%
BRTX
BioRestorative Therapies
0.21
-1.28
-85.91%
BOLT
Bolt Biotherapeutics
3.95
-1.65
-29.46%
Faeth Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Faeth Therapeutics Adopts Performance-Based Stock Option Plan
Positive
Jul 23, 2026
On July 21, 2026, Faeth Therapeutics’ board approved one-time performance-based stock option grants under its 2026 Equity Incentive Plan for employees employed as of February 19, 2026, including CEO Anand Parikh and former named executive of...
Business Operations and StrategyPrivate Placements and Financing
Faeth Therapeutics Launches New At-the-Market Equity Program
Neutral
Jun 18, 2026
On June 18, 2026, Faeth Therapeutics, Inc. entered into a sales agreement with TD Securities (USA) LLC to establish an at-the-market equity offering program under which it may, from time to time, sell up to $150 million of common stock, with the a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.